OMERS Buys Stakes in Biotech Tech Firms
OMERS Buys Stakes in Biotech Tech Firms
Anonymous
Key Points
1
IDEAYA Biosciences shows highly concentrated institutional ownership (98.29% of the stock held by hedge funds and institutions) beyond OMERS’ 20,500-share stake (~$764,000), with notable recent moves by several funds: Farther Finance Advisors up 171.1% to 919 shares (~$32,000), ANTIPODES PARTNERS Ltd up 49.4% to 1,150 shares (~$40,000), Quantbot Technologies LP opening a new position (~$43,000), and Daiwa Securities Group Inc. increasing to 3,141 shares (~$66,000).
2
Stoke Therapeutics saw a broad influx of new institutional positions alongside OMERS’ 30,000-share buy (~$982,000), including BlackRock, Deutsche Bank, and Bank of New York Mellon opening new stakes. In addition, JPMorgan Chase & Co initiated coverage with an overweight rating and a $40 price target, while analysts set targets ranging from $39 to $60 (BTIG, Guggenheim, Canaccord Genuity), contributing to a consensus of ten Buy ratings and one Sell.
3
ACADIA Pharmaceuticals’ 2Q activity included OMERS’ purchase of 33,500 shares (~$848,000). Other institutions added stakes as well, notably Connor Clark & Lunn Investment Management, Emerald Investment Advisers, Ieq Capital, Virtus Advisers and E Fund Management. A notable insider move: EVP Elizabeth H.Z. Thompson sold 16,558 shares on July 30 at an average price of $26.13, reducing her holding by about 46% to roughly 18,994 shares (~$496,000).
4
Neurocrine Biosciences (NBIX) saw OMERS acquire 5,210 shares (~$878,000) in Q2, mirrored by other funds adding to positions (e.g., DJE Kapital AG; Geneos Wealth Management; Meeder Asset Management; Basecamp Wealth Advisors; Cassaday & Co Wealth Management). Analyst coverage actions included Sanford C. Bernstein initiating NBIX with an Outperform rating; Morgan Stanley lowering the target from $196 to $182 with an Equal Weight rating; Piper Sandler lifting its NBIX target in a separate note.
OMERS Administration Corp deployed nearly $5 million across five public biotech and tech companies in the second quarter, signaling renewed institutional confidence in the sector. The Canadian pension fund bought stakes in IDEAYA Biosciences, Stoke Therapeutics, ACADIA Pharmaceuticals, Neurocrine Biosciences, and Gartner, joining a wave of hedge funds and asset managers building positions watchlistnews.
OMERS Spreads Bets Across Biotech Pipeline
OMERS' largest Q2 purchase was 33,500 shares of ACADIA Pharmaceuticals for $848,000 watchlistnews. The fund also acquired 30,000 shares of Stoke Therapeutics for $982,000 and 20,500 shares of IDEAYA Biosciences valued at $764,000 tickerreport. In Neurocrine Biosciences, OMERS bought 5,210 shares worth $878,000, while taking a smaller $666,000 position in Gartner Inc. with 5,139 shares.
Stoke Therapeutics Attracts Analyst Upgrade
Stoke Therapeutics drew broad institutional interest beyond OMERS' stake tickerreport. JPMorgan Chase initiated coverage with an overweight rating and set a $40 price target. Other analysts ranged from $39 to $60, creating a consensus of ten Buy ratings against one Sell. BlackRock, Deutsche Bank, and Bank of New York Mellon all opened new positions in the company.
ACADIA Insider Selling Offsets Fund Buying
While OMERS and other institutional buyers added to ACADIA Pharmaceuticals holdings, an executive moved in the opposite direction watchlistnews. EVP Elizabeth H.Z. Thompson sold 16,558 shares on July 30 at $26.13 per share, cutting her stake by 46% to roughly $496,000. Other institutions including Connor Clark & Lunn Investment Management and Emerald Investment Advisers increased their positions during the quarter.
Neurocrine Mixed Signals From Analyst Community
Neurocrine Biosciences drew conflicting analyst views as OMERS and other funds built stakes. Sanford C. Bernstein initiated coverage with an Outperform rating, supporting the buying momentum. Morgan Stanley took a different view, lowering its price target from $196 to $182 with an Equal Weight rating. Piper Sandler meanwhile lifted its price target in a separate note, showing the split opinion on the biotech stock.
IDEAYA Concentration Reflects Hedge Fund Dominance
IDEAYA Biosciences shows extreme institutional dominance, with 98.29% of shares held by hedge funds and large investors. Beyond OMERS' position, other funds made aggressive moves in Q2. Farther Finance Advisors surged 171.1% to 919 shares ($32,000), while Quantbot Technologies LP opened a new $43,000 position. Daiwa Securities Group and ANTIPODES PARTNERS also expanded their holdings, signaling confidence in the company's trajectory.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
12
Articles
2
Reach
14
Topics
A
AnonymousAuthor
